With the enormous leaps now being made in amyloid imaging, researchers are pushing back the diagnostic timeline, identifying patients at the very onset of mild cognitive impairment—and perhaps even before any memory complaints appear.
“A drug like semagacestat would be interesting to study in patients at that stage. Don't chuck the product altogether; back it up into an earlier phase and see if the results are any different.”
'My fear is that a drug will be shelved when in fact it might be a good choice in a presymptomatic scenario.'
Source DR. SABBAGH